Pipeline Pre-clinical


Aberrant migration and proliferation of cancer cells are the hallmark of metastatic tumors. Using our unique discovery platformMigHit™ the company has identified novel synthetic small molecule which inhibit selectively the migration and survival of hematological as well as solid cancer cells, but not normal cells.

BKT-300 was Identified, utilizing Biokines Might™ phenotypic screen. BKT-300 is the first in class small molecule that specifically controls migration and survival pathways in cancer cells via targeting the protein regulator of cytokinesis 1 (PRC1), a novel less explored target.

BKT300 Selectively binds and inhibits the function of protein regulator of cytokinesis 1 ( PRC1), a new validated tumor target. Its specifically induces cell cycle arrest and apoptosis of tumour cells but not normal cells by downregulating the expression of CDC25c (cell division cycle 25C) in tumor cells. BKT300 Inhibits cancer cell migration by inhibition of F-actin and microtubules formation. BKT300 is a powerful immunoregulatory agent. In-vitro BKT300  synergizes with SoC therapies in inhibiting tumor cell growth including: BCL-2 inhibitor Ventoclax, topoisomerase inhibitor Irinotecan, and alkylating agent Temozolomide. In-vivo BKt300 Demonstrates potent inhibition of tumor growth in multiple in vivo mouse models including PDXs. Currently BKT300 is in IND enabling studies, 12 months to IND submission, pre-IND meeting planned to Q2 2021. BKT300 has a strong worldwide IP coverage (life span till 2042) including a composition of matter and method of use patents

Recent News

Pre-Clinical Programs